Repository logo
 
Publication

Establishment of 2D Cell Cultures Derived From 3D MCF‐7 Spheroids Displaying a Doxorubicin Resistant Profile

dc.contributor.authorNunes, Ana Raquel Santos
dc.contributor.authorCosta, Elisabete C.
dc.contributor.authorBarros, Andreia
dc.contributor.authorDiogo, Duarte Miguel de Melo
dc.contributor.authorCorreia, Ilídio Joaquim Sobreira
dc.date.accessioned2018-12-11T10:04:17Z
dc.date.available2018-12-11T10:04:17Z
dc.date.issued2018-09
dc.description.abstractIn vitro 3D cancer spheroids generally exhibit a drug resistance profile similar to that found in solid tumors. Due to this property, these models are an appealing for anticancer compounds screening. Nevertheless, the techniques and methods aimed for drug discovery are mostly standardized for cells cultured in 2D. The development of 2D cell culture models displaying a drug resistant profile is required to mimic the in vivo tumors, while the equipment, techniques, and methodologies established for conventional 2D cell cultures can continue to be employed in compound screening. In this work, the response of 3D‐derived MCF‐7 cells subsequently cultured in 2D in medium supplemented with glutathione (GSH) (antioxidant agent found in high levels in breast cancer tissues and a promoter of cancer cells resistance) to Doxorubicin (DOX) is evaluated. These cells demonstrated a resistance toward DOX closer to that displayed by 3D spheroids, which is higher than that exhibited by standard 2D cell cultures. In fact, the 50% inhibitory concentration (IC50) of DOX in 3D‐derived MCF‐7 cell cultures supplemented with GSH is about eight‐times higher than that obtained for conventional 2D cell cultures (cultured without GSH), and is only about two‐times lower than that attained for 3D MCF‐7 spheroids (cultured without GSH). Further investigation revealed that this improved resistance of 3D‐derived MCF‐7 cells may result from their increased P‐glycoprotein (P‐gp) activity and reduced production of intracellular reactive oxygen species (ROS).pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationNunes, A.S., Costa, E.C., Barros, A.S., de Melo-Diogo, D., Correia, I.J. (2018) "Establishment of 2D cell cultures derived from 3D MCF-7 spheroids displaying a Doxorubicin resistant profile", Biotechnology journal, pp. 1800268.pt_PT
dc.identifier.doi10.1002/biot.201800268pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.6/6608
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherWileypt_PT
dc.relationHealth Sciences Research Centre
dc.relation3D multicellular spheroids as high throughput platforms to screen novel combinatory therapies for treatment of pancreatic cancer
dc.relationMULTIFUNCTIONAL GRAPHENE-OXIDE NANOCARRIERS FOR DRUG DELIVERY AND PHOTOTHERMAL THERAPY OF LUNG CANCER
dc.relation.publisherversionhttps://onlinelibrary.wiley.com/doi/full/10.1002/biot.201800268pt_PT
dc.subject2D cell culturespt_PT
dc.subjectBreast cancerpt_PT
dc.subjectDoxorubicinpt_PT
dc.subjectDrug resistancept_PT
dc.subjectGlutathionept_PT
dc.subjectSpheroidspt_PT
dc.titleEstablishment of 2D Cell Cultures Derived From 3D MCF‐7 Spheroids Displaying a Doxorubicin Resistant Profilept_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardTitleHealth Sciences Research Centre
oaire.awardTitle3D multicellular spheroids as high throughput platforms to screen novel combinatory therapies for treatment of pancreatic cancer
oaire.awardTitleMULTIFUNCTIONAL GRAPHENE-OXIDE NANOCARRIERS FOR DRUG DELIVERY AND PHOTOTHERMAL THERAPY OF LUNG CANCER
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UID%2FMulti%2F00709%2F2013/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT//SFRH%2FBD%2F103507%2F2014/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT//SFRH%2FBD%2F103506%2F2014/PT
oaire.citation.startPage1800268pt_PT
oaire.citation.titleBiotechnology Journalpt_PT
oaire.fundingStream6817 - DCRRNI ID
person.familyNameda Rocha Costa
person.familyNameSousa Barros
person.familyNameMiguel de Melo Diogo
person.familyNameJoaquim Sobreira Correia
person.givenNameElisabete Cristina
person.givenNameAndreia Sofia
person.givenNameDuarte
person.givenNameIlídio
person.identifierC2z5x04AAAAJ
person.identifierUMbJ1KMAAAAJ
person.identifier.ciencia-idB314-4CF0-6633
person.identifier.ciencia-idC213-C723-4528
person.identifier.ciencia-id9C10-9BD8-634E
person.identifier.ciencia-idF610-7373-DC81
person.identifier.orcid0000-0002-0490-0095
person.identifier.orcid0000-0002-0522-1705
person.identifier.orcid0000-0001-9984-3603
person.identifier.orcid0000-0003-1613-9675
person.identifier.scopus-author-id55805850100
person.identifier.scopus-author-id56266511300
person.identifier.scopus-author-id7003557499
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.embargofctCopyright cedido à editora no momento da publicaçãopt_PT
rcaap.rightsclosedAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationbfc28f1b-bd1b-4564-97e3-ae6a0c3b6c0c
relation.isAuthorOfPublication3f895ebf-cc75-46fd-9357-31fd5e104503
relation.isAuthorOfPublication8525f1be-ff8f-4e46-b158-e59928e8a3e5
relation.isAuthorOfPublicationf2c3e779-34a2-4309-950a-80687664c6ad
relation.isAuthorOfPublication.latestForDiscovery8525f1be-ff8f-4e46-b158-e59928e8a3e5
relation.isProjectOfPublication1bea56d9-b91c-42af-a6d6-8004792eaac0
relation.isProjectOfPublicationf7269f43-1c1e-4809-9b13-8bf68efc42c6
relation.isProjectOfPublicationa61e1cb2-bd08-4ddf-806d-76b237068ee3
relation.isProjectOfPublication.latestForDiscovery1bea56d9-b91c-42af-a6d6-8004792eaac0

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
2018 Nunes-Biotechnology_Journal.pdf
Size:
2.85 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: